A041703: A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for PH-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease

Title
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for PH-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
Principal Investigator
Emadi, Ashkan
Phase
II (Cancer Control)
Age Group
Adult
Applicable Disease Sites
Leukemia
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Abby Swiger, RN
Research Nurse
Phone: +1 304-293-1683
Email:

View on ClinicalTrials.gov